Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles British Journal of Haematology Year : 2021

Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant

Benoît Tessoulin
Embargoed file
Embargoed file
Ne sera jamais visible

Dates and versions

inserm-03542571 , version 1 (25-01-2022)

Identifiers

Cite

Amandine Le Bourgeois, Marianne Coste‐burel, Thierry Guillaume, Pierre Peterlin, Alice Garnier, et al.. Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant. British Journal of Haematology, 2021, pp.10.1111/bjh.17911. ⟨10.1111/bjh.17911⟩. ⟨inserm-03542571⟩
18 View
2 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More